248 related articles for article (PubMed ID: 15124419)
1. A brand new bag. Trauma-care revolution among benefits touted as blood substitute enters critical phase of clinical trials.
Becker C
Mod Healthc; 2004 Apr; 34(15):30-1, 34. PubMed ID: 15124419
[No Abstract] [Full Text] [Related]
2. Oxygen carriers ("blood substitutes").
Topfer LA; Hailey D
Issues Emerg Health Technol; 2001 Jul; (21):1-6. PubMed ID: 11776287
[TBL] [Abstract][Full Text] [Related]
3. Emergency research and consent: keeping the exception from undermining the rule.
Derse AR
Am J Bioeth; 2006; 6(3):36-7; discussion W49-50. PubMed ID: 16754448
[No Abstract] [Full Text] [Related]
4. Artificial oxygen carriers: a current review.
Henkel-Honke T; Oleck M
AANA J; 2007 Jun; 75(3):205-11. PubMed ID: 17591302
[TBL] [Abstract][Full Text] [Related]
5. Rules is rules.
Orr RD
Am J Bioeth; 2006; 6(3):40-1; discussion W49-50. PubMed ID: 16754450
[No Abstract] [Full Text] [Related]
6. Blood on tap. Part 1. History in the making.
Whitehead S
Emerg Med Serv; 2004 Feb; 33(2):41-8. PubMed ID: 14994671
[TBL] [Abstract][Full Text] [Related]
7. Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia.
Smani Y
Curr Opin Investig Drugs; 2008 Sep; 9(9):1009-19. PubMed ID: 18729008
[TBL] [Abstract][Full Text] [Related]
8. Not blood simple.
Stokstad E
Science; 2002 Feb; 295(5557):1003. PubMed ID: 11834812
[No Abstract] [Full Text] [Related]
9. Baxter's blood substitute OK'd for trauma testing.
Hensley S
Mod Healthc; 1996 Dec; 26(49):16. PubMed ID: 10162699
[No Abstract] [Full Text] [Related]
10. An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial.
Kipnis K; King NM; Nelson RM
Am J Bioeth; 2006; 6(3):18-21. PubMed ID: 16754441
[TBL] [Abstract][Full Text] [Related]
11. PolyHeme. Northfield Laboratories.
Jahr JS; Varma N
IDrugs; 2004 May; 7(5):478-82. PubMed ID: 15154110
[TBL] [Abstract][Full Text] [Related]
12. Blood substitutes: the future is now.
Moore EE
J Am Coll Surg; 2003 Jan; 196(1):1-17. PubMed ID: 12517544
[No Abstract] [Full Text] [Related]
13. Use of substitution for blood draws ethics challenge.
Burton TM
Wall St J (East Ed); 2006 Mar; ():A2. PubMed ID: 16642578
[No Abstract] [Full Text] [Related]
14. Unproven or unsatisfactory versus equipoise in emergency research with waived consent.
Spellecy R
Am J Bioeth; 2006; 6(3):44-5. PubMed ID: 16754452
[No Abstract] [Full Text] [Related]
15. Blood-substitute study is criticized by U.S. agency.
Burton TM
Wall St J (East Ed); 2006 Mar; ():A3. PubMed ID: 16578912
[No Abstract] [Full Text] [Related]
16. Trials and errors: barriers to oversight of research conducted under the emergency research consent waiver.
Kipnis K; King NM; Nelson RM
IRB; 2006; 28(2):16-9. PubMed ID: 16770884
[No Abstract] [Full Text] [Related]
17. The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents.
Sloan EP
Intensive Care Med; 2003 Mar; 29(3):347-9. PubMed ID: 12710459
[No Abstract] [Full Text] [Related]
18. Trauma trials leave ethicists uneasy.
Dalton R
Nature; 2006 Mar; 440(7083):390-1. PubMed ID: 16554766
[No Abstract] [Full Text] [Related]
19. Ethical considerations concerning South Africa's approval of a blood substitute.
Schutte AE
Ethics Med; 2002; 18(2):55-62. PubMed ID: 14700041
[No Abstract] [Full Text] [Related]
20. When a long shot is worth a shot.
Jacobs T; Fischer J
Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
